Galectin-3: A Novel Biomarker Predicts Sudden Cardiac Death in Hypertrophic Cardiomyopathy

Emet S., Dadashov M., Sonsoz M. R., Cakir M. O., Yilmaz M., Elitok A., ...More

AMERICAN JOURNAL OF THE MEDICAL SCIENCES, vol.356, no.6, pp.537-543, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 356 Issue: 6
  • Publication Date: 2018
  • Doi Number: 10.1016/j.amjms.2018.08.013
  • Journal Name: AMERICAN JOURNAL OF THE MEDICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.537-543
  • Keywords: Sudden cardiac death, Galectin-3, Ventricular arrhythmias, Hypertrophic cardiomyopathy, Risk score, INDEPENDENT MARKER, ABNORMALITIES, ARRHYTHMIAS, DIAGNOSIS, RISK
  • Istanbul University Affiliated: Yes

Abstract

Background: Hypertrophic cardiomyopathy is a primary cardiac disease characterized by left ventricular hypertrophy, myocyte hypertrophy and irregularities and interstitial fibrosis in the absence of any cardiac or systemic diseases and may lead to sudden cardiac death (SCD). Galectin-3 is a P-galactoside-binding lectin that has been associated with cardiac fibrosis and inflammation. In this study, we aimed to investigate the relationship between serum galectin-3 levels and the criteria for 5-year sudden death risk, recently defined in the European Society of Cardiology guidelines (2014), in patients with hypertrophic cardiomyopathy.